Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro
References on tuberculosis research, including WHO reports, new TB vaccines, drug resistance, and treatment regimens.
Antibiotics and Antimycotics Market Size to Hit $91.54 Billion, Globally at 5.2% CAGR by 2031
The antibiotics and antimycotics market is projected to reach $91.54 billion by 2031, driven by infectious disease prevalence and R&D initiatives. Key players include Pfizer, Novartis, and Sanofi. North America leads in revenue, with APAC expected to show highest growth.
Gilead's Livdelzi Seladelpar Demonstrated a Sustained Efficacy and Long Term Safety
Gilead Sciences announces 81% of PBC patients achieve durable biochemical response with Livdelzi by Month 30, with 41% achieving ALP normalization. Livdelzi also reduces pruritus severity, with 27% near resolution in moderate to severe cases. The safety profile remains robust, with no treatment-related SAEs reported.
Tuberculosis Through Time: Historic Burden, Modern Challenges
Tuberculosis (TB) remains a significant global health challenge, with most cases occurring in low- and middle-income countries. Despite advancements in diagnosis and treatment, TB is the second leading infectious killer worldwide after COVID-19. The COVID-19 pandemic led to an underdiagnosis of TB, resulting in increased cases and deaths. TB is an airborne disease primarily treated with antibiotics, but drug-resistant strains require more toxic treatments. The BCG vaccine is used in high-TB-prevalence countries to prevent severe TB in children.
Study Finds Ezetimib, Rifampin May Increase Coproporphyrin Concentrations in Healthy Patients
Single-dose ezetimibe increases serum coproporphyrin I (CPI) in healthy patients, and coadministration with rifampin enhances CPI levels and OATP1B1 inhibition, suggesting greater risk of drug interactions.
Pulmonology Drug Approvals and Recalls, Medical Device Updates
FDA approved RSV and pneumococcal vaccines, updated Sirturo for TB, cleared Huxley SANSA for sleep apnea, and issued recalls for Ivenix, RMU-2000, Volara System, Infusomat Space, ClotTriever XL, Plum 360, and Vivo 45 LS devices.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath